Araco Marco, Quagliana Angelo, Pedrazzini Giovanni, Valgimigli Marco
Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Interventional Cardiology Department, via Tesserete 48, 6900 Lugano, Switzerland.
Eur Heart J Case Rep. 2021 Oct 26;5(11):ytab428. doi: 10.1093/ehjcr/ytab428. eCollection 2021 Nov.
Complex and high-risk coronary intervention (CHIP-PCI) and PCI in cardiogenic shock complicating acute coronary syndrome (ACS) are increasingly performed under mechanical circulatory support-so-called protected PCI. Among the available options, Impella Cardiac Power (CP) heart pump (Abiomed) is percutaneously inserted over the femoral artery and typically requires a second arterial access to perform PCI, which further enhances the risk of vascular and bleeding complications. The single-access technique allows Impella CP placement and PCI performance through the same vascular access. When a 7 Fr system is desirable, only a long and entirely hydrophilic coated sheath has been previously used, which is not available in Europe.
A 85-year-old patient admitted with non ST-elevation - acute coronary syndrome (NSTE-ACS), severely reduced left ventricular function and three-vessel coronary artery disease underwent single-access CHIP-PCI under Impella CP support. After a failed attempt to insert a standard 7 Fr long femoral sheath alongside the Impella catheter, we successfully introduced a 7.5 Fr sheathless guiding catheter and delivered the planned percutaneous treatment with the benefits conferred by a 7 Fr-rather than 6-lumen catheter, without the need for an additional arterial access.
This is, to the best of our knowledge, the first case of CHIP-PCI performed under Impella support utilizing the single-access technique with a 7.5 Fr sheathless guiding catheter. Beyond advantages of the single-access technique in sparing time and avoiding vascular complications associated with gaining a second arterial access, the lower outer diameter of the sheathless catheter compared with standard 7 Fr sheaths may allow improved limb perfusion and lower chance of interference with the Impella CP catheter.
复杂高危冠状动脉介入治疗(CHIP-PCI)以及急性冠状动脉综合征(ACS)合并心源性休克时的PCI越来越多地在机械循环支持下进行,即所谓的保护性PCI。在现有选择中,Impella心脏动力(CP)心脏泵(Abiomed公司)经皮经股动脉插入,通常需要第二个动脉通路来进行PCI,这进一步增加了血管和出血并发症的风险。单通路技术允许通过同一血管通路放置Impella CP并进行PCI。当需要7Fr系统时,以前仅使用过长且完全亲水涂层的鞘管,而该鞘管在欧洲无法获得。
一名85岁患者因非ST段抬高型急性冠状动脉综合征(NSTE-ACS)、左心室功能严重降低和三支冠状动脉疾病入院,在Impella CP支持下接受了单通路CHIP-PCI。在尝试将标准7Fr长股鞘管与Impella导管一起插入失败后,我们成功引入了7.5Fr无鞘引导导管,并在7Fr而非6腔导管带来的益处下进行了计划中的经皮治疗,无需额外的动脉通路。
据我们所知,这是首例在Impella支持下利用单通路技术和7.5Fr无鞘引导导管进行的CHIP-PCI病例。除了单通路技术在节省时间和避免与获得第二个动脉通路相关的血管并发症方面的优势外,与标准7Fr鞘管相比,无鞘导管的外径更小,可能有助于改善肢体灌注,并降低干扰Impella CP导管的几率。